Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants

Nirsevimab, a monoclonal antibody with an extended half-life, is designed to protect infants from respiratory syncytial virus disease after a single intramuscular dose. This placebo-controlled trial involving 1447 preterm infants at 164 sites in 23 countries assessed the effectiveness of nirsevimab...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine Jg. 383; H. 5; S. 415 - 425
Hauptverfasser: Griffin, M. Pamela, Yuan, Yuan, Takas, Therese, Domachowske, Joseph B, Madhi, Shabir A, Manzoni, Paolo, Simões, Eric A.F, Esser, Mark T, Khan, Anis A, Dubovsky, Filip, Villafana, Tonya, DeVincenzo, John P
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Massachusetts Medical Society 30.07.2020
Schlagworte:
Antibodies
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - adverse effects
Antiviral Agents - administration & dosage
Antiviral Agents - adverse effects
FDA approval
Female
Gestation
Gestational age
Health care
Hospitalization
Hospitalization - statistics & numerical data
Humans
Hypersensitivity
Incidence
Infant
Infant, Newborn
Infant, Premature
Infants
Infections
Injection
Injections, Intramuscular
Kaplan-Meier Estimate
Laboratories
Life Sciences
Male
Monoclonal antibodies
Newborn babies
Pharmacokinetics
Poisson Distribution
Premature babies
Prophylaxis
Respiratory diseases
Respiratory syncytial virus
Respiratory Syncytial Virus Infections - epidemiology
Respiratory Syncytial Virus Infections - prevention & control
Respiratory Syncytial Virus, Human
Respiratory tract diseases
Respiratory Tract Infections - epidemiology
Respiratory Tract Infections - prevention & control
Respiratory Tract Infections - virology
Vaccines
Viral Fusion Proteins - antagonists & inhibitors
Vitamin E
Writers
United States > US
ISSN:0028-4793, 1533-4406, 1533-4406
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Nirsevimab, a monoclonal antibody with an extended half-life, is designed to protect infants from respiratory syncytial virus disease after a single intramuscular dose. This placebo-controlled trial involving 1447 preterm infants at 164 sites in 23 countries assessed the effectiveness of nirsevimab over 150 days after the dose was administered.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa1913556